Welcome to our dedicated page for Option Care Health news (Ticker: OPCH), a resource for investors and traders seeking the latest updates and insights on Option Care Health stock.
Option Care Health, Inc. provides home and alternate-site infusion services for patients with acute and chronic conditions across the United States. The company operates in infusion services and reports developments tied to clinical service delivery, national provider relationships, and the economics of its care model.
Recurring news for OPCH includes quarterly and full-year financial results, guidance updates, operating cash flow, share repurchase activity, credit facility changes, and presentations at health care investor conferences. Company updates also address capital allocation and management commentary related to revenue growth and profitability in home and alternate-site infusion care.
Option Care Health, the largest independent provider of home and alternate site infusion services in the U.S., announced they will present at the William Blair Virtual Growth Stock Conference on June 11, 2020. CEO John Rademacher and CFO Mike Shapiro are set to speak at 8:00 a.m. CDT. A live audio webcast of the presentation will be available, along with a replay, on their investor relations website. Option Care Health employs over 5,000 teammates, including approximately 2,900 clinicians, dedicated to enhancing patient care across all 50 states.
Option Care Health (NASDAQ: OPCH) has been chosen by UroGen Pharma (NASDAQ: URGN) as a preferred national pharmacy provider for the delivery of Jelmyto™, a new cancer treatment for low-grade upper tract urothelial cancer. This first-in-class treatment combines mitomycin with a hydrogel technology for effective tumor targeting. Approved by the FDA on April 15, 2020, Jelmyto requires specialized preparation and delivery, which Option Care Health’s nationwide network of USP 800 pharmacies can provide, ensuring safety and compliance. This partnership enhances patient access to innovative therapies.
Option Care Health (Nasdaq: OPCH) reported strong financial results for Q1 2020, highlighting net revenue of $705.4 million, a 48% increase from Q1 2019. Gross profit rose to $158.0 million, representing 22.4% of net revenue. Despite a net loss of $19.9 million ($0.11 per share), the company achieved an adjusted EBITDA of $40.2 million, up 107.6%. Cash flow from operations reached $18.4 million, up 102.7%. The company has maintained cash balances of $77.2 million with no borrowings on its revolver. Future impacts of COVID-19 on referrals and costs remain uncertain.
Summary not available.